Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

Veligrotug demonstrated strong long-term durability and efficacy in Phase 3 THRIVE trials for thyroid eye disease, meeting ...